A thrombotic microangiopathy (TMA) occurs when a patient presents with microangiopathic hemolytic anemia, thrombocytopenia and organ damage. There are many causes of TMAs, but thrombotic thrombocytopenic purpura (TTP) must always be considered because of its high mortality rate. Treatment with therapeutic plasma exchange and transfusions can reduce the mortality rate but those treatments carry their own morbidity. Severe cobalamin deficiency can cause a clinical picture similar to TTP. Understanding the pathologic changes of this pseudo-TTP can allow physicians to suspect this difference early in the clinical course. In the following case, elevations in homocysteine and methylmalonic acid, as well as changes in the CBC, allowed this distinction to be identified early, minimizing potentially dangerous treatments.
Introduction
Thrombotic microangiopathy (TMA) is defined as a clinicopathological entity characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage. 1, 2, 3, 4 TMAs are rare, with an estimated incidence of 4 per 1 million, 1, 5, 6 but have a mortality rate of 10-20%. 1 Hemolytic Uremic Syndrome, cancer, HIV, hemopoetic stem cell transplant, connective tissue disorders and medications, like oxymorphone, Quinine, calcinuerin inhibitors and antineoplastic agents, can result in TMA. 3, 5, 7, 8 The most common TMA is thrombotic thrombocytopenic purpura (TTP), or Moschowitz disease, with 2-3 individuals per million incidence. 5 Acute TTP episodes, whether in congenital or acquired forms, have a high mortality rate, and the treatment is invasive and comes with considerable risk. 3, 7, 9, 10 Cobalamin (Vitamin B12) deficiency has a prevalence of 4-15%, which is higher in the elderly. 1, 6, 9, 11, 12 Most symptomatology is mild, but lifethreatening manifestations can occur. Cobalamin deficiency related TMA, which accounts for 2.5% of all TMA cases and called pseudo-TTP. 13 Understanding the differences between TTP and pseudo-TTP is essential for rapid diagnosis, allowing for appropriate treatment and minimizing potential harm to the patient.
Case Presentation
A 60 year old female, who was last seen in her normal state of health one week ago, was found down with vacillating levels of consciousness, disorientation and incomprehensible speech. As she lived alone, no recent history could be obtained and her comorbidities were not immediately known. Physical examination showed an alert but disoriented patient with a scalp hematoma along with some generalized bruising. Vital signs demonstrated a fever with tachycardia and tachypnea, while laboratory work up (Table  1) showed acute kidney injury and rhabdomyolysis. Her CBC revealed a macrocytotic anemia with thrombocytopenia. Followup blood work demonstrated an elevated LDH but normal haptoglobin and reticulocyte count. A peripheral smear demonstrated schistocytes, anisopoikiocytosis and hypersegmented neutrophils. Suspecting a microangiopathic process, solumedrol was started, Nephrology was consulted for plasmophoresis and the patient was transfused fresh frozen plasma and leukocyte reduced red blood cells. Noting an elevated MCV, more labs were obtained. B12 level was low but methylmalonic acid (MMA) and homocysteine levels were both high, indicating cobalamin deficiency. B12 was replaced parenterally.
IV fluids were started for her rhabdomyolysis and both kidney function and cardiac isoenzymes were monitored. CT of her head showed no acute changes. Blood and urine cultures were obtained and antibiotics were started. The next day, improvement was seen in her mentation, kidney function and troponin levels. Plasmapheresis was discontinued after one treatment and she didn't require further transfusions. Forty-eight hours after admission, cultures returned negative and antibiotics were discontinued. On hospital day three, she transitioned out of the ICU and old records confirmed medical history of diabetes, hypertension and hyperlipidemia. Two days later, ADAMTS-13 antibodies returned Cobalamin Deficient Thrombotic Microangiopathy: a Case of TTP or Pseudo-TTP WVMJ OA as normal, officially dispelling the diagnosis of TTP. Slowly, with physical therapy, she grew stronger and was discharged to a skilled nursing facility for further physical therapy. Because intrinsic factor and antiparietal cell antibodies were found, plans for outpatient EGD by GI to evaluate for atrophic gastritis was planned. (Table 2 )
Discussion
Thrombotic Thrombocytopenic Purpura (TTP) TTP is a rare condition characterized by a "pentad" of microangiopathic hemolytic anemia, fever, thrombocytopenia, renal dysfunction, and neurologic manifestations. 3, 5, 6, 8, 9, 14 It is caused by a severe deficiency of ADAMTS-13 metalloproteinase, which cleaves ultra-large von Willebrand factor (ulvWF) multimers. 3, 5, 6, 7, 8, 9, 10, 15 In a deficiency of < 10% of this gamma immunoglobulin, ulvWF strings form in the microcirculation encouraging platelet deposition. This results in thrombocytopenia and obstruction of microvasculature with resultant damage to erythrocytes. 3, 4, 5, 6, 9, 10 TTP occurs in one of two ways.
Case Report | WVMJ OA Other adjunctive treatments include steroids, immunosupressants, N-acetyl cysteine and as a last result, splenectomy.
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Cobalamin Physiology & Pathophysiology
In order to understand pseudo-TTP, one first must understand cobalamin metabolism. The body stores of 3-5 mg are maintained, despite a 50-60% absorption rate, by the recommended daily intake of 2.4 µg. 11, 12 Dietary sources of cobalamin are of animal origin: meat, eggs, and dairy. 11, 12, 14, 15 It is released from food by gastric secretions in the stomach and pancreatic secretions in the duodenum. It binds to intrinsic factor, secreted from gastric parietal cells, and this B12-IF complex is internalized by the cubam receptor in the terminal ileum for release into the plasma. Transcobalamin then binds cobalamin for uptake into the cell. 3, 11, 12 Also, biliary cobalamin can be reabsorbed through the enterohepatic system and stored in the liver. 11 Dietary cobalamin deficiency is rare in developed countries 11, 13, 15 with the exceptions of malnourished and vegetarian/vegan populations. 3, 11, 15 Absorption can also be effected by medication effect limiting gastric and pancreatic acid or altered microbiota. Other causes include alcohol excess, hypothyroidism, liver disease, myelodysplastic syndrome and the fish tapeworm Diphyllobothrium. 3, 7, 8, 11, 12, 14 The most common reason for cobalamin deficiency is pernicious anemia, a slow acting autoimmune mechanism disrupting the IF-Cobalamin absorption. 2, 3, 11, 12, 14 Bariatric surgery associated parietal cell removal or removal of the terminal ileum mimics this with surgical suddenness. 3, 11 Cobalamin is a required cofactor in two biochemical reactions: the conversion of methylmalonyl CoA to succinyl CoA and the methylation of homocysteine to methionine. The former is used for energy production in the citric acid cycle and the latter eventually produces purines and pyrimidines ( Figure  1) . 3, 7, 11, 12 Deficiency impairs DNA synthesis delaying migration of the DNA replication fork and annealing DNA fragments of the lagging strand, arresting maturation of hematopoietic cell precursors. 6, 8, 9, 11, 16 This creates ineffective erythropoiesis by intramedullary apoptosis in the marrow, but intravascularly, the asynchronous maturation of nucleus and cytoplasm create large erythrocytes with rigid but fragile cell membranes, 3, 6, 10, 11, 13, 14, 15, 16 prone to hemolysis with sheering stress (Figure 2 ). Homocysteine accumulation causes that stress with endothelial damage, vasoconstriction, activation of the coagulation system and platelet aggregation. 3, 6, 7, 10, 13, 14, 15 WVMJ OA Case Report | This combined pathology results in pseudo-TTP. Plasma infusions and plasma exchange do little to treat pseudo-TTP. Treatment usually requires parenteral replacement of cobalamin, 2,3,6,7,10,11 although 1-5% of high dose oral supplementation can be absorbed through passive GI diffusion, which has been found to be adequate in studies. 3, 11, 12 Differentiation between TTP and Pseudo-TTP Distinguishing between these two pathologies is difficult. Both are microangiopathies that result in hemolytic anemias. 1, 2, 3, 4, 7, 13, 15 This is evident by diminished Hgb/Hct, elevated bilirubin, elevated LDH and schistocytes in the peripheral circulation denoting fragmented cells. Thrombocytopenia occurs from platelet aggregation, with the resultant debris eventually causing organ ischemia leading to dysfunction and failure, especially in the brain, heart, kidney and gastrointestinal system. 8, 12, 13 This progression occurs most often in TTP but can also be seen in pseudo-TTP if severe enough. The etiologies are different, with TTP initiated by a decrease in the ADAMTS-13 activity, 3, 5, 6, 7, 8, 9 while pseudo-TTP combines the fragility of erythrocytes enlarged by ineffective erythropoiesis with homocysteine induced endothelial damage, vasoconstriction, platelet aggregation and coagulation activation. 3, 7, 10, 11, 13, 14, 15, 16 Other clues to differences between TTP and pseudo-TTP are elucidated when effects of cobalamin deficiency are considered. Having no cobalamin cofactor, MMA and homocysteine significantly increase. This allows both to be used as markers for B12 deficiency. 3, 7, 11, 13 The inefficient hematopoiesis limits compensatory erythrocyte production, blunting the reticulocyte count.
1,2,6,10 It also allows immature cells, such as megakaryocytes, nucleated erythrocytes and hypersegmented neutrophils, to be seen in peripheral circulation. 8, 11, 14, 15 The megaloblastic features of the larger erythrocytes are seen as an elevated MCV. 1, 11, 12 Ineffective erythropoiesis also contributes to intramedullary hemolysis, causing LDH to be significantly more elevated than intravascular cell destruction only. 1, 6, 7, 8, 9, 10, 13, 14, 15 Finally, age can be a clue with most TTP occurring prior to fifty years old 13 while pseudo-TTP predominately occurs in seniors. 1, 6, 9, 12 This patient didn't present with a clear picture for pseudo-TTP (Table  1) . From her labs, she clearly had a microangiopathic hemolytic anemia with thrombocytopenia and purpura. The acute kidney injury, troponemia and altered mental status speaks to TTP's organ dysfunction. But a better interpretation is likely Rhabdomyolysis, from a likely fall with prolonged immobility. This exacerbated her kidney failure and subsequent cardiac isoenzyme accumulation. Normal ADAMTS-13 could have immediately excluded TTP, but results take several days to return. Therefore, because of the risk of near fatal TTP, plasma exchange was initiated immediately despite the treatment's 2.3% mortality risk and 24% major morbidity risk. 3, 7, 9 Fortunately, cobalamin deficiency was suspected immediately from the immature cells and increased MCV on her initial CBC. This was soon confirmed with low cobalamin level and elevated MMA and homocysteine levels, allowing rapid administration of parenteral cobalamin and cessation of a potentially more dangerous therapeutic option.
Conclusion
Because of the near fatal progression of TTP, plasma exchange should be initiated in any TMA despite its risks. Even with the rarity of cobalamin deficiency in developed countries, cobalamin deficient TMA should be assessed in all suspected TTP cases. Early diagnosis of cobalamin deficiency allows more accurate and appropriate treatment, avoiding unnecessary risk.
